 |
Corporate News
03-Aug-21
|
|
|
|
|
|
|
|
|
|
|
|
Natco Pharma transfers Lenalidomide Capsules ANDA to Arrow International
|
|
|
|
|
|
|
|
Natco Pharma announced that it has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International as per an earlier agreement between the parties.
This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.
Arrow International (an affiliate of Teva Pharmaceutical Industries) is the marketing partner of NATCO for this product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the
2.5mg and 20mg strengths.
|
|
|
|
Previous News |
Natco Pharma fixes record date for interim dividend
(
Market Beat
-
Reports
09-Aug-23
15:22
)
|
|
|
Natco Pharma Ltd spurts 5.12%, rises for fifth straight session
(
Hot Pursuit
-
11-Jun-24
13:00
)
|
|
|
Natco Pharma to conduct board meeting
(
Corporate News
-
06-Nov-23
15:32
)
|
|
|
Natco Pharma invests US$2 million in Cellogen Therapeutics
(
Hot Pursuit
-
18-Jan-24
10:49
)
|
|
|
Natco Pharma consolidated net profit declines 22.51% in the December 2022 quarter
(
Results
-
Announcements
09-Feb-23
14:54
)
|
|
|
Natco Pharma receives warning letter from USFDA for its Kothur unit
(
Corporate News
-
09-Apr-24
10:35
)
|
|
|
Natco Pharma
(
Results
-
Analysis
30-May-23
11:27
)
|
|
|
Natco Pharma to conduct board meeting
(
Corporate News
-
23-May-23
11:49
)
|
|
|
Natco Pharma consolidated net profit declines 40.00% in the December 2020 quarter
(
Results
-
Announcements
11-Feb-21
16:25
)
|
|
|
Natco Pharma Ltd spurts 1.64%, gains for third straight session
(
Hot Pursuit
-
29-May-23
13:05
)
|
|
|
Natco Pharma
(
Results
-
Analysis
14-Feb-22
21:40
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|